Effects of metabolic cancer therapy on tumor microenvironment
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F86652036%3A_____%2F22%3A00569552" target="_blank" >RIV/86652036:_____/22:00569552 - isvavai.cz</a>
Alternative codes found
RIV/00064203:_____/22:10452795 RIV/00216208:11110/22:10452795 RIV/00216208:11310/22:10452795
Result on the web
<a href="https://www.frontiersin.org/articles/10.3389/fonc.2022.1046630/full" target="_blank" >https://www.frontiersin.org/articles/10.3389/fonc.2022.1046630/full</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3389/fonc.2022.1046630" target="_blank" >10.3389/fonc.2022.1046630</a>
Alternative languages
Result language
angličtina
Original language name
Effects of metabolic cancer therapy on tumor microenvironment
Original language description
Targeting tumor metabolism for cancer therapy is an old strategy. In fact, historically the first effective cancer therapeutics were directed at nucleotide metabolism. The spectrum of metabolic drugs considered in cancer increases rapidly clinical trials are in progress for agents directed at glycolysis, oxidative phosphorylation, glutaminolysis and several others. These pathways are essential for cancer cell proliferation and redox homeostasis, but are also required, to various degrees, in other cell types present in the tumor microenvironment, including immune cells, endothelial cells and fibroblasts. How metabolism-targeted treatments impact these tumor-associated cell types is not fully understood, even though their response may co-determine the overall effectivity of therapy. Indeed, the metabolic dependencies of stromal cells have been overlooked for a long time. Therefore, it is important that metabolic therapy is considered in the context of tumor microenvironment, as understanding the metabolic vulnerabilities of both cancer and stromal cells can guide new treatment concepts and help better understand treatment resistance. In this review we discuss recent findings covering the impact of metabolic interventions on cellular components of the tumor microenvironment and their implications for metabolic cancer therapy.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Frontiers in Oncology
ISSN
2234-943X
e-ISSN
2234-943X
Volume of the periodical
12
Issue of the periodical within the volume
DEC 13 2022
Country of publishing house
CH - SWITZERLAND
Number of pages
20
Pages from-to
1046630
UT code for WoS article
000902458000001
EID of the result in the Scopus database
2-s2.0-85145082976